FSAD - Women’s Health Study
A Phase 2b, Multi-Center, Multiple-Dose, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy And Safety Of Sildenafil Cream, 3.6% In Premenopausal Patients With Female Sexual Arousal Disorder (FSAD)
CONDITION: Female Sexual Arousal Disorder
HEALTHY PARTICIPANTS: Yes
LOCATION: UH Cleveland Medical Center
The purpose of this study is to find out if the investigational drug, topical Sildenafil Cream, 3.6%, increases genital arousal in women during sexual activity.
Who Can Participate
Women 18 years and older who may be experiencing female sexual arousal disorder may be eligible for this study. There are certain requirements that must be met to participate in the study for both you and your partner. Your partner will need to be available throughout your participation in the study and must meet certain criteria to participate in the study. If your partner does not meet these criteria, you also will not be eligible to participate.